ArticlePloS one2013
MiR-376c down-regulation accelerates EGF-dependent migration by targeting GRB2 in the HuCCT1 human intrahepatic cholangiocarcinoma cell line.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Molecular Targets and Signaling Pathways in Cholangiocarcinoma: A Systematic Review.Asian Pacific journal of cancer prevention : APJCP · 2023Pooled it
- Nanoparticle hydrogel system delivery of miR-494-3p to improve tendon healing by targeting CXXC4.Gene therapy · 2026Article
- Unique miRomics Expression Profiles inInternational journal of molecular sciences · 2023Article
- Establishment and verification of potential biomarkers for cholangiocarcinoma.Experimental and therapeutic medicine · 2022Article
- MicroRNA-629-5p promotes osteosarcoma proliferation and migration by targeting caveolin 1.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021Article
- Exosomal noncoding RNAs in cholangiocarcinoma: Laboratory noise or hope?World journal of gastrointestinal surgery · 2020Review
- Review
- LncRNA PCAT6 increased cholangiocarcinoma cell proliferation and invasion via modulating miR-330-5p.American journal of translational research · 2019Article
- Hsa-miR-376c-3p targets Cyclin D1 and induces G1-cell cycle arrest in neuroblastoma cells.Oncology letters · 2018Article
- Article
- MicroRNA (miR)-433 and miR-22 dysregulations induce histone-deacetylase-6 overexpression and ciliary loss in cholangiocarcinoma.Hepatology (Baltimore, Md.) · 2018Article
- NcRNAs and Cholangiocarcinoma.Journal of Cancer · 2018Review
- Aberrant DNA Methylation as a Biomarker and a Therapeutic Target of Cholangiocarcinoma.International journal of molecular sciences · 2017Review
- Serum microRNA-376 family as diagnostic and prognostic markers in human gliomas.Cancer biomarkers : section A of Disease markers · 2017Article
- The role of microRNAs in intrahepatic cholangiocarcinoma.Journal of cellular and molecular medicine · 2017Review
- The role of miRNAs in cholangiocarcinoma.Hepatic oncology · 2016Review
- The Emerging Role of miRNAs and Their Clinical Implication in Biliary Tract Cancer.Gastroenterology research and practice · 2016Review
- EGFR Signaling in Liver Diseases.International journal of molecular sciences · 2015Review
- miR-200c dampens cancer cell migration via regulation of protein kinase A subunits.Oncotarget · 2015Article
- MicroRNAs in the Cholangiopathies: Pathogenesis, Diagnosis, and Treatment.Journal of clinical medicine · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNA miR-376c was expressed in normal intrahepatic biliary epithelial cells (HIBEpiC), but was significantly suppressed in the HuCCT1 intrahepatic cholangiocarcinoma (ICC) cell line. The biological significance of the down-regulation of miR-376c in HuCCT1 cells is unknown. We hypothesized that miR-376c could function as a tumor suppressor in these cells. To test this hypothesis, we sought the targets of miR-376c, and characterized the effect of its down-regulation on HuCCT1 cells. We performed proteomic analysis of miR-376c-overexpressing HuCCT1 cells to identify candidate targets of miR-376c, and validated these targets by 3'-UTR reporter assay. Transwell migration assays were performed to study the migratory response of HuCCT1 cells to miR-376c overexpression. Furthermore, microarrays were used to identify the signaling that were potentially involved in the miR-376c-modulated migration of HuCCT1. Finally, we assessed epigenetic changes within the potential promoter region of the miR-376c gene in these cells. Proteomic analysis and subsequent validation assays showed that growth factor receptor-bound protein 2 (GRB2) was a direct target of miR-376c. The transwell migration assay revealed that miR-376c significantly reduced epidermal growth factor (EGF)-dependent cell migration in HuCCT1 cells. DNA microarray and subsequent pathway analysis showed that interleukin 1 beta and matrix metallopeptidase 9 were possible participants in EGF-dependent migration of HuCCT1 cells. Bisulfite sequencing showed higher methylation levels of CpG sites upstream of the miR-376c gene in HuCCT1 relative to HIBEpiC cells. Combined treatment with the DNA-demethylating agent 5-aza-2'-deoxycytidine and the histone deacetylase inhibitor trichostatin A significantly upregulated the expression of miR-376c in HuCCT1 cells. We revealed that epigenetic repression of miR-376c accelerated EGF-dependent cell migration through its target GRB2 in HuCCT1 cells. These findings suggest that miR-376c functions as a tumor suppressor. Since metastasis is the major cause of death in ICC, microRNA manipulation could lead to the development of novel anti-cancer therapy strategies for ICC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.